scholarly journals Optical Quantification of Cellular Mass, Volume, and Density of Circulating Tumor Cells Identified in an Ovarian Cancer Patient

2012 ◽  
Vol 2 ◽  
Author(s):  
Kevin G. Phillips ◽  
Carmen Ruiz Velasco ◽  
Julia Li ◽  
Anand Kolatkar ◽  
Madelyn Luttgen ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patient ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Ovarian Cancer Patient ◽  
Mass Volume

PD-1/PD-L1 checkpoint inhibitors in combination with olaparib display antitumor activity in ovarian cancer patient-derived three-dimensional spheroid cultures

2021 ◽  
Vol 70 (3) ◽  
pp. 843-856
Author(s):  
Kathryn M. Appleton ◽  
Ashley K. Elrod ◽  
Katy A. Lassahn ◽  
Stephen Shuford ◽  
Lillia M. Holmes ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Antitumor Activity ◽  
Cancer Patient ◽  
Ovarian Cancer Patient ◽  
Checkpoint Inhibitors ◽  
Three Dimensional

Ovarian cancer patient with germline mutations in both BRCA1 and NBN genes

2008 ◽  
Vol 186 (2) ◽  
pp. 122-124 ◽  
Author(s):  
Nathalia V. Porhanova ◽  
Anna P. Sokolenko ◽  
Nathalia Yu. Sherina ◽  
Daria N. Ponomariova ◽  
Nathalia N. Tkachenko ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patient ◽  
Ovarian Cancer Patient ◽  
Germline Mutations

scholarly journals Development and Validation for Prognostic Nomogram of Epithelial Ovarian Cancer Recurrence based on Circulating Tumor Cells and Epithelial–Mesenchymal Transition

2020 ◽  
Author(s):  
Jiani Yang ◽  
Jun Ma ◽  
Yue Jin ◽  
Shanshan Cheng ◽  
Shan Huang ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Risk Stratification ◽  
Epithelial Ovarian Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Epithelial Mesenchymal Transition ◽  
Ca 125 ◽  
Mesenchymal Transition ◽  
Cox Regression Analysis ◽  
Significant Difference

Abstract We aimed to determine prognosis value of circulating tumor cells(CTCs) undergoing epithelial–mesenchymal transition(EMT) in epithelial ovarian cancer(EOC) recurrence. We used CanPatrol CTC-enrichment technique to detect CTCs from blood samples and classify subpopulations into epithelial, mesenchymal and hybrids. To construct nomogram, prognostic factors were selected by Cox regression analysis. Risk stratification was performed through Kaplan–Meier analysis among training group(n=114) and validation group(n=38). By regression screening, both CTC counts(HR 1.187; 95%CI 1.098-1.752; p=0.012) and M-CTC(HR 1.098; 95%CI 1.047-1.320; p=0.009) were demonstrated as independent factors for recurrence. Other variables including pathological grade, FIGO stage, lymph node metastasis, ascites and CA-125 were also collected(p < 0.005) to construct nomogram. The C-index of internal and external validation for nomogram was 0.913 and 0.874. We found significant predictive value for nomogram with/without CTCs (AUC 0.8705 and 0.8097). Taking CTC counts and M-CTC into separation, the values were 0.8075 and 0.8262. Finally, survival curves of risk stratification based on CTC counts(p=0.0241), M-CTC(p=0.0107) and the nomogram(p=0.0021) were drawn with significant difference. In conclusion, CTCs could serve as a novel factor for EOC prognosis. Nomogram model constructed by CTCs and other clinical parameters could predict EOC recurrence and perform risk stratification for clinical decision-making.Trial registration: Chinese Clinical Trial Registry, ChiCTR-DDD-16009601, October 25, 2016

Sign in / Sign up

Export Citation Format

Share Document